AC Immune unveils first-in-class Morphomer targeting pathological α-synuclein
April 15, 2025
Researchers from AC Immune SA recently presented the discovery of ACI-21018, a novel α-synuclein aggregation inhibitor developed using AC Immune’s proprietary Morphomer platform.
